PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20943044-5	2010	Expression of CD4+ T cell activation markers was measured in induced sputum at baseline and after 1, 4, 8 and 12 weeks of treatment by flow cytometry, which showed a down-regulation of HLA-DR and CD25 surface proteins in the budesonide group, compared with the control group; these differences resulted as being statistically significant through weeks 4-12.	Budesonide	225-235	interleukin 2 receptor subunit alpha	Homo sapiens	196-200	
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	interleukin 2 receptor subunit alpha	Homo sapiens	187-191	
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	interleukin 2 receptor subunit alpha	Homo sapiens	267-271	
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	interleukin 2 receptor subunit alpha	Homo sapiens	43-47	
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	interleukin 2 receptor subunit alpha	Homo sapiens	92-96	
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	interleukin 2 receptor subunit alpha	Homo sapiens	92-96	
25722071-7	2015	Budesonide was able to increase the expression of TLR4, TLR2 and IL-10 in CD4+/CD25 highly+ cells from asthmatics.	Budesonide	0-10	interleukin 2 receptor subunit alpha	Homo sapiens	79-83	
35468610-2	2022	The study was aimed to assess the influence of budesonide nasal spray on CD8+CD25+Foxp3+ Tregs and to evaluate their cellular functions in neutrophilic chronic rhinosinusitis with nasal polyps (CRSwNPs).	Budesonide	47-57	interleukin 2 receptor subunit alpha	Homo sapiens	77-81